Latest Conference Coverage

The chief medical officer at Mandos Health discussed new CNS 2025 data on adrabetadex in infantile-onset Niemann-Pick type C and the growing evidence of its potential disease-modifying impact.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the 2025 AANEM Annual Meeting!

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Rebecca Edelmayer, PhD. [LISTEN TIME: 14 minutes]

A groundbreaking trial compares nipocalimab and efgartigimod for treating generalized myasthenia gravis, promising new insights for patient care.

A perspective model aimed noted that introducing efgartigimod alfa for patients with chronic inflammatory demyelinating polyneuropathy incurs more expected costs.

Patients with generalized myasthenia gravis reported a positive experience with rozanolixizumab self-administration, with a preference for the manual push method.

An open-label extension trial testing the efficacy of nipocalimab in patients transitioning from placebo revealed continued improvement in MG-Activities of Daily Living scores over a long-term period.

Data showed that efgartigimod led to greater improvements in disease activity compared with placebo in idiopathic inflammatory myopathy, and improvements in seronegative myasthenia gravis.

An analysis of the first 110 patients screened for the ARISE study showed that an independent adjudication committee confirmed the diagnosis of CIDP in nearly 3-quarters of cases.

Exenatide shows effects on brain metabolism in Parkinson disease but fails to provide clinical benefits, as recent trials reveal mixed results.

The professor of clinical neuroscience at Newcastle University discussed selecting appropriate and representative patient populations across different phases of clinical trials for Parkinson disease. [WATCH TIME: 5 minutes]

Riley Bove, MD, an associate professor of neurology at the University of California, San Francisco, discussed phase 4 findings from the MINORE and SOPRANINO studies that examined ocrelizumab exposure during pregnancy and lactation in women with MS.

Mark Forman, MD, PhD, chief medical officer at Ventyx Biosciences, discussed promising early-stage data of VTX3232, an NLRP3 inflammasome in development for early-stage Parkinson disease.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 54th Child Neurology Society (CNS) Annual Meeting, held October 8-11, 2025.

Neurology News Network for the week ending October 25, 2025. [WATCH TIME: 4 minutes]

At CNS 2025, the associate professor of neurology and pediatrics at the University of Virginia discussed using educational model frameworks to prepare child neurology trainees for clinical practice. [WATCH TIME: 3 minutes]

James N. Brenton, MD, director of the Pediatric MS and Related Disorders Clinic at the University of Virginia, discussed how lifestyle modification and multidisciplinary care can support disease management in children with multiple sclerosis.

At CNS 2025, the program director of child neurology residency at Boston Children's Hospital discussed strategies to expose medical students to child neurology early in their clinical training. [WATCH TIME: 4 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 2025 International Congress of Parkinson’s Disease and Movement Disorders (MDS).

Clinical trial data presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders showed that pimavanserin had positive efficacy in patients showing Parkinson Disease psychosis symptoms who were treated earlier.

New findings reveal early treatment with Trappsol Cyclo shows promise for young patients with Niemann-Pick disease type C1, enhancing safety and efficacy.

The president and founder of the Stuttering Treatment and Research Society highlighted the significance of interdisciplinary care for both children and adults with stuttering. [WATCH TIME: 5 minutes]

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

David Stamler, MD, CEO at Alterity Therapeutics, gave clinical perspectives on ATH434, an emerging agent showing promise in phase 2 studies of multiple system atrophy.

A recent review of studies over the past decade, presented at CNS 2025, suggests that the ketogenic diet can significantly reduce seizure frequency in children with drug-resistant epilepsy.

A new study reported that children and adolescents with Tourette syndrome on dopamine D2 receptor antagonists had higher rates of psychiatric and metabolic adverse events than those unexposed.

The executive vice president and head of R&D at Lundbeck provided more context on the scientific rationale of amlenetug, an investigational monoclonal antibody designed to halt the spread of alpha-synuclein aggregates in multiple system atrophy. [WATCH TIME: 3 minutes]

Late breaking data from a phase 1 trial presented at MDS 2025 showed that cell therapy UX-DA001 demonstrated positive efficacy in a woman with moderate-to-advanced Parkinson disease.